Lexaria Bioscience Corp.
Lexaria Bioscience Corp.
Latest News
Latest Event
Special Meeting of Shareholders
Email Alerts
Sign up today and receive company updates straight to your inbox.
Company Overview
Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 36 patents granted and many patents pending worldwide.
IR Contacts
Headquarters
Canadian Operations
#100-740 McCurdy RoadKelowna, BC V1X 2P7
US Operations
2226 W. Northern AvenuePhoenix, AZ 85021
Investor Relations
IR contact
T: 250-765-6424 ext. 202
IR@lexariabioscience.com
Transfer Agent
Computershare Investor Services Inc.
T: 800-564-6253
https://www.computershare.com
Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.